Cytokinetics Retains Development and Commercialization Rights to Ispinesib and SB-743921
News Dec 29, 2008
GlaxoSmithKline (GSK) and Cytokinetics, Incorporated have announced that GSK has informed Cytokinetics that it will not exercise its option to license ispinesib or SB-743921 as provided under the Collaboration and License Agreement entered into by the companies in 2001.
All rights to ispinesib and SB-743921, each novel inhibitors of kinesin spindle protein (KSP), will revert to Cytokinetics, on agreed terms. The collaboration between Cytokinetics and GSK will continue, and will be focused on the development by GSK of GSK-923295, an inhibitor of centromere-associated protein-E (CENP-E).
“The seven year collaboration between Cytokinetics and GSK has generated three novel drug candidates now in clinical development,” said Paolo Paoletti, MD Senior Vice President of GSK Oncology R&D.
“The decision by GSK to not exercise options on ispinesib and SB-743921 was the result of a shift in portfolio direction for GSK. We continue to believe that the novel mechanism of anti-mitotics may bring hope to cancer patients, reflected in GSK’s ongoing development of GSK-923295 under its collaboration with Cytokinetics,” Paoletti said.
“While we are disappointed in this outcome, we understand GSK’s business decision. We are encouraged by the safety and tolerability of each of ispinesib and SB-743921 as well as the amplified activity observed with the more dose-dense scheduling of these novel drug candidates,” stated Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “We are committed to advancing these two drug candidates through to the end of Phase I and will then evaluate the next steps for ispinesiband SB-743921 in context of the results, required funding and other partnering possibilities.”
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019